We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Seattle Genetics to Present on ADC Technology

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Seattle Genetics, Inc. has announced that it will report preclinical advances with its antibody-drug conjugate (ADC) technology during the 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 14-18, 2005 at the Pennsylvania Convention Center in Philadelphia.

In addition, two of Seattle Genetics' collaborators, CuraGen and MedImmune, will make presentations regarding their ADC programs utilizing Seattle Genetics' technology.

"We are continuing to make significant strides with our ADC technology, which we employ in our own product pipeline, including SGN-35 and SGN-75, as well as license to leading biotechnology and pharmaceutical companies," stated Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics.

"The presentations at this conference by Seattle Genetics and our collaborators demonstrate some of the key advances being made with our technology to empower the next generation of targeted cancer therapies."

ADCs are monoclonal antibodies linked to potent cell-killing drugs. Due to the targeting ability of monoclonal antibodies, ADCs are capable of delivering a cell-killing payload directly to a tumor cell, while minimizing toxicity to healthy cells.

Seattle Genetics has developed improved ADC technology utilizing stable, enzyme-cleavable linkers to deliver synthetic, highly-potent cytotoxic payloads.

The linkers are stable in the bloodstream and release the drug payload once inside target cells.

In this poster presentation, the company will describe the properties of one of its cell-killing drug payloads, monomethyl auristatin F (MMAF).

ADCs utilizing MMAF were designed to transport the drug into target cells, resulting in a potent agent compared to free drug in certain preclinical models.

In addition, the poster includes data on a series of ADCs in which various linker components were altered or deleted.

The findings suggest that modifications to the linker can lead to new ADCs with improved therapeutic indices.

In addition, two of Seattle Genetics' ADC collaborators will present the following abstracts during poster sessions:

- CuraGen Corporation -"Treatment parameters modulating regression of human melanoma xenografts in situ by an antibody-drug conjugate (CR011-vcMMAE) targeting gpNMB-expressing tumor cells" (Abstract A70)

- MedImmune Inc. -"Targeting of EphA2 on tumor cells with antibodies conjugated to monomethyl auristatin F" (Abstract B75)